Gene expression profiling identifies responsive patients with cancer of unknown primary treated with carboplatin, paclitaxel, and everolimus: NCCTG N0871 (alliance)(†)

BACKGROUND: Carboplatin (C) and paclitaxel (P) are standard treatments for carcinoma of unknown primary (CUP). Everolimus, an mTOR inhibitor, exhibits activity in diverse cancer types. We did a phase II trial combining everolimus with CP for CUP. We also evaluated whether a gene expression profiling...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Ann Oncol
Main Authors: Yoon, H. H., Foster, N. R., Meyers, J. P., Steen, P. D., Visscher, D. W., Pillai, R., Prow, D. M., Reynolds, C. M., Marchello, B. T., Mowat, R. B., Mattar, B. I., Erlichman, C., Goetz, M. P.
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2016
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4907341/
https://ncbi.nlm.nih.gov/pubmed/26578722
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdv543
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados